<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718105</url>
  </required_header>
  <id_info>
    <org_study_id>1512-MAD-067-JG</org_study_id>
    <nct_id>NCT02718105</nct_id>
  </id_info>
  <brief_title>Maternal and Fetal Compatibility in Assisted Reproductive Technology (ART)-Oocyte Donor Influences Live Birth Rate</brief_title>
  <official_title>Maternal Killer Cell Immunoglobulin-like Receptors (KIR) and Fetal (Human Leukocyte Antigen) HLA-C Compatibility in ART-oocyte Donor Influences Live Birth Rate a Prospective Controlled Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Has the maternal KIR haplotype an impact in pregnancy, miscarriage and live birth rates per
      embryo transfer in donor oocytes -ART by paternal and oocyte donor HLA-C?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of maternal KIR haplotype and parental, donors HLA-C, could predict which
      couple can benefit for the selection of single embryo transfer (SET)/double embryo transfer
      (DET), or donor selection by HLA-C in ART, in order to increase the live birth rate
      (LBR)/cycle since HLA-C1/C1 donors are predicted to be safer and C2/C2 males or oocyte donors
      may be mor &quot;dangerous&quot; as identified by epidemiological studies
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compatibility maternal fetal KIR HLA-C</measure>
    <time_frame>2 years</time_frame>
    <description>KIR haplotype regions will be defined by the presence of the following KIR genes: Cen-A/2DL3: Tel-A/3DL1 and 2DS4; Cen-B/2DL2 and 2DS2; Tel-B/2DS1 and 3DS1. The HLA-C ligands for KIRs will be divided into 2 groups: HLA-C1 and HLA_C2</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Receiver patients in donor oocyte -ART</arm_group_label>
    <description>Maternal and fetal compatibility KIR HLA-C determinations in ART -oocyte donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>KIR HLAC determinations</intervention_name>
    <description>We will take blood samples for KIR HLA-C determinations.</description>
    <arm_group_label>Receiver patients in donor oocyte -ART</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Genomic DNA will be obtained and will be studied in Professor Moffet laboratory in Cambridge
      (department of Patholog√≠, University of Cambridge) KIR typing including copi number and HLA-C
      loci will be performed as previously described (Hiby 2010, Jiang 2012). KIR haplotype regions
      will be defined by the presence of the following KIR genes: Cen-A/2DL3; Tel-A/3DL1 and 2DS4;
      Cen-B/2DL2 and 2DS2; Tel-B/2DS1 and 3DS1. The HLA-C ligands for KIRs will be divided into 2
      groups: HLA-C1 and HLA-C2.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing an assisted reproductive treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 19 - 27 kg/m2

          -  Blastocyst embryo transfer previous.

          -  Normal karyotype, thrombophylic and immunological results.

          -  Normal clinical history, viral serology, hormonal analysis (TSH, T4, prolactin,
             estrogen, progesterone), spermiogram, sperm FISH and pelvic ultrasound results.

        Exclusion Criteria:

          -  Pregnancy women.

          -  Psychiatric disorders.

          -  Uterus alterations.

          -  Polycystic ovary syndrome

          -  Genetic and autoimmune diseases.

          -  Infectious diseases.

          -  Corticoid and immunosuppressant treatments previous.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Antonio Garcia Velasco, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan Antonio Garcia Velasco, PhD</last_name>
    <phone>91 180 29 00</phone>
    <email>Juan.Garcia.Velasco@ivi.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Alesandru, PhD</last_name>
    <phone>91 180 29 00</phone>
    <email>Diana.Alesandru@ivi.es</email>
  </overall_contact_backup>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IVI Madrid</investigator_affiliation>
    <investigator_full_name>Juan A Garcia-Velasco</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>KIR HLA-C</keyword>
  <keyword>ART</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

